摘要
目的:观察来氟米特联合雷公藤多苷治疗IgA肾病的临床效果。方法:将IgA肾病患者80例随机分为治疗组和对照组,各40例。治疗组给予来氟米特联合雷公藤多苷,对照组给予依那普利,疗程均为12个月。结果:治疗组总有效率为87.5%(35/40),对照组为62.5%(25/40),差异有统计学意义(χ2=12.56,P<0.05)。治疗组治疗后尿蛋白为(0.63±0.21)g/24 h,血清白蛋白为(41.32±13.42)g/L,均较治疗前及与对照组治疗后差异有统计学意义(均P<0.05)。结论:两药联用治疗IgA肾病患者能提高患者的血清白蛋白,显著降低患者的尿蛋白,副作用少。
Objective： To observe the clinical efficacy of Leflunomide combined with Tripterygium Wilfordii on IgA nephropathy.Methods： 80 patients were randomly divided into treatment group and control group,each group contained 40 cases.The treatment group was given Leflunomide combined with Tripterygium Wilfordii,and the control group with given Enalapril,and both group continued for therapeutical period of 12 months.Results： Total effective rate of treatment group with 87.5% was obviously higher than the control group′s 62.5%,and there was statistical difference（χ2=12.56,P〈0.05）.After treatment,urine protein of treatment group was（0.63±0.21） g/24h,and serum albumin was（41.32±13.42） g/L,both compared with those of control group has statistical difference（all P〈0.05）.Conclusion： Leflunomide combined with Tripterygium Wilfordii could difinitely reduce urine protein and raise serum albumin of IgA nephropathy,with less side effect.
出处
《中国医药导报》
CAS
2011年第11期67-68,共2页
China Medical Herald
关键词
IGA肾病
来氟米特
雷公藤多苷
IgA nephropathy
Leflunomide
Tripterygium Wilfordii
